APPROVED PRODUCTS

Learn more about our currently approved products in the U.S. and other major worldwide markets.

More information
Array, our products
BEACON CRC, active clinical trial BEACON CRC, active clinical trial

Phase 3 BEACON CRC trial

BEACON CRC

Find out more about one of Array’s pivotal clinical trials, BEACON CRC, which is currently active.

Learn More

We are focusing in on key targets and pathways to treat disease

We are focused on the discovery and development of targeted small molecules that inhibit molecular pathways involved in disease progression.

Find out How
Targeted research to discover targeted small molecules Targeted research to discover targeted small molecules
Array is using its discovery platform to develop therapies to treat cancer Array is using its discovery platform to develop therapies to treat cancer

We are using our foundation in science to find new compounds to treat cancer and other diseases

Our sights are set on developing therapies to treat cancer and other high-burden diseases, where we aim to impact as many patients as possible.

Discover How

Latest News

06/17/2019
Pfizer to Acquire Array BioPharma
06/04/2019
Array BioPharma to Present at the Goldman Sachs 40ᵗʰ Annual Global Healthcare Conference
05/29/2019
Array BioPharma to Present at the Jefferies 2019 Global Healthcare Conference
05/29/2019
Array BioPharma Announces Presentation of Updated Overall Survival from the Phase 3 COLUMBUS Trial of BRAFTOVI + MEKTOVI in advanced BRAF-mutant Melanoma at 2019 ASCO Annual Meeting
05/21/2019
Array BioPharma Announces BRAFTOVI + MEKTOVI + Cetuximab Meet Primary Endpoints of ORR and OS in Phase 3 BEACON CRC Trial Interim Analysis for the Treatment of BRAF(V600E)-mutant Metastatic Colorectal Cancer
ALL NEWS

BRAFTOVI® and MEKTOVI® are registered trademarks of Array BioPharma Inc. in the United States and various other countries.